全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

网膜动脉参与原发性肝癌血供之影像特征及栓塞治疗的临床价值

, PP. 816-820

Keywords: 原发性肝癌,经导管肝动脉化疗栓塞,大网膜动脉,完全性栓塞

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的探讨大网膜动脉参与原发性肝癌血供的影像特征及完全性栓塞治疗的临床价值。方法收集本院2010-2014年行经导管肝动脉化疗栓塞(transcatheterarterialchemoembolization,TACE)治疗发现大网膜动脉(omentalartery,OA)参与原发性肝癌供血患者的影像及临床资料,回顾性分析OA参与肿瘤供血时的影像特征,评估OA完全性栓塞治疗的安全性及有效性。结果36名患者于41次TACE治疗发现OA参与肿瘤供血。病灶均突破肝包膜,病灶位于肝S4、5段且于大网膜方向突破者13例(31.7%),位于肝S5、6段且向下方外生生长者18例(43.9%)。53支OA参与肿瘤供血,血管造影特征明显。49支OA(92.5%)成功超选择性插管并完全性栓塞,未发现严重并发症。mRECIST方法分析28例,完全缓解(completeresponse,CR)9例,病灶强化半径至少减小30%为部分缓解(partialresponse,PR)13例,既未达到缓解也未达到进展标准者为稳定(stabledisease,SD)2例,病灶强化半径至少增加30%为进展(progressivedisease,PD)4例,OA供血病灶栓塞有效率(responserate,RR)为78.6%,肿瘤生长控制率(diseasecontrolrate,DCR)为85.7%。再次行TACE治疗15例,仅2例(13.3%)可见新生OA参与肿瘤供血。结论OA多参与位于肝S4~6段,并突破肝包膜或侵犯大网膜的大肝癌供血,血管造影特征明显。完全性栓塞OA肿瘤供血支安全性高,疗效好。

References

[1]  El-Serag H B. Hepatocellular Carcinoma[J]. N Engl J Med, 2011, 365(12): 1118-1127. [2]Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90. [3]Murata S, Mine T, Sugihara F, et al. Interventional treatment for unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(37): 13453-13465. [4]Nishikawa H, Kita R, Kimura T, et al. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients[J]. J Cancer, 2014, 5(7): 590-597. [5]李强, 杨仁杰, 朱旭, 等. 肝外侧支动脉参与肝癌供血的介入治疗[J]. 中华肿瘤杂志, 2013, 35(8): 613-617. [6]Miyayama S, Matsui O, Taki K, et al. Extrahepatic blood supply to hepatocellular carcinoma:? angiographic demonstration and transcatheter arterial chemoembolization[J]. Cardiovasc Intervent Radiol, 2006, 29(1): 39-48. [7]Miyayama S, Matsui O, Akakura Y, et al. Hepatocellular carcinoma with blood supply from omental branches: treatment with transcatheter arterial embolization[J]. J Vasc Interv Radiol, 2001, 12(11): 1285-1290. [8]罗小平, 淦伟. 大肝癌大网膜动脉供血的DSA表现及其超选择性栓塞治疗的临床价值[J]. 实用放射学杂志, 2008, 24(11): 1565-1567. [9]Lencioni R, Llovet J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. [10]Miyayama S, Yamashiro M, Okuda M, et al. Anastomosis between the hepatic artery and the extrahepatic collateral or between extrahepatic collaterals: observation on angiography[J]. J Med Imaging Radiat Oncol, 2009, 53(3): 271-282. [11]Paul S B, Gamanagatti S R, Mukund A, et al. Transarterial chemoembolization for hepatocellular carcinoma: Significance of extrahepatic collateral supply[J]. Indian J Cancer, 2011, 48(3): 339-344. [12]Chung J W, Kim H C, Yoon J H, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients[J]. Korean J Radiol, 2006, 7(4): 257-266. [13]Gao S, Yang R J, Dong J H. Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization[J]. Chin J Cancer Res, 2012, 24(3): 207-212. [14]Miyayama S, Yamashiro M, Okuda M, et al. The march of extrahepatic collaterals: analysis of blood supply to hepatocellular carcinoma located in the bare area of the liver after chemoembolization[J]. Cardiovasc Intervent Radiol, 2010, 33(3): 513-522. [15]Won J Y, Lee D Y, Lee J T, et al. Supplemental transcatheter arterial chemoembolization through a collateral omental artery: treatment for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2003, 26(2): 136-140. [16]Miyayama S, Yamashiro M, Shibata Y, et al. Variations in feeding arteries of hepatocellular carcinoma located in the left hepatic lobe[J]. Jpn J Radiol, 2012, 30(6): 471-479. [17]田利, 王茂强, 李强, 等. 网膜支动脉参与肝癌供血的介入治疗研究[J]. 中国医药指南, 2009, 7(7): 13-14, 23. [18]李强, 王茂强, 宋鹏, 等. 网膜动脉栓塞化疗在肝癌治疗中的价值[J]. 中华消化外科杂志, 2008, 7(6): 425-427.
[2]  孔祥如,王珊,章均,等.TACE治疗不可切除型肝母细胞瘤早期不良反应事件的回顾性分析[J].第三军医大学学报,2014,36(12):1341.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133